Breast Cancer News and Research

Latest Breast Cancer News and Research

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.

27 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

Low vitamin D could account for link between obesity and cancer, heart disease, diabetes

Overweight or obese women with less-than-optimal levels of vitamin D who lose more than 15 percent of their body weight experience significant increases in circulating levels of this fat-soluble nutrient, according to a new study by researchers at Fred Hutchinson Cancer Research Center.

26 May 2011

Neoprobe, Devicor sign gamma detection device asset purchase agreement

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has signed a definitive asset purchase agreement to sell its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in cash, plus a contingent value provision for payment to Neoprobe of up to an additional $20 million in royalties.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Lipofilling seems to be safe for breast cancer patients, study suggests

A new study has gone some way to answering the question about whether or not a technique called lipofilling is safe for women who are having their breasts reconstructed after surgery for breast cancer.

25 May 2011

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

Genomic Health, Inc. today announced positive preliminary results from a study of Oncotype DX in patients with DCIS by the Eastern Cooperative Oncology Group, a clinical trials cooperative group supported by the National Cancer Institute.

25 May 2011

New cancer study finds benefit in old therapy

Cancer patients who used a 5,000-year-old combination of gentle exercise and meditation experienced significantly higher wellbeing levels, improved cognitive functioning and less inflammation compared to a control group, new University of Sydney research has found.

24 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Researchers discover protein switch that can trigger heart failure

Researchers at the Peter Munk Cardiac Centre discovered a protein switch which can trigger a cascade of events leading to heart failure, pointing to a new direction for drug development.

24 May 2011

Variant of obesity gene may increase breast cancer risk

New research aimed to better identify the genetic factors that lead to breast cancer has uncovered a link between the fat mass and obesity associated gene and a higher incidence of breast cancer.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Scientists find new drug target in breast cancer

Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

23 May 2011

Researchers identify new drug resistant protein in breast cancer

Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

23 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Breast cancer survivors, advocates stress importance of Every Woman Counts program

Responding to Governor Brown's announced revised budget, breast cancer survivors and advocates from across the state stressed the importance of early detection.

21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

Breast Cancer News and Research

Latest Breast Cancer News and Research

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Low vitamin D could account for link between obesity and cancer, heart disease, diabetes

Neoprobe, Devicor sign gamma detection device asset purchase agreement

Lx Therapies, BioCis partner to form Laurantis Pharma

Lipofilling seems to be safe for breast cancer patients, study suggests

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

New cancer study finds benefit in old therapy

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Researchers discover protein switch that can trigger heart failure

Variant of obesity gene may increase breast cancer risk

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Scientists find new drug target in breast cancer

Researchers identify new drug resistant protein in breast cancer

FDA approves SUTENT for treatment of pancreatic NET

Breast cancer survivors, advocates stress importance of Every Woman Counts program

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Breast Cancer News and Research

Latest Breast Cancer News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in